Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data
FDA advisory panel members decided Dec. 7 that the benefit of drug-eluting stent use in FDA-approved indications outweighs the risks. But the panel expressed some skepticism about the strength of data measuring the long-term incidence of blood clots
More from Archive
More from Medtech Insight
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.
The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.